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Persistent hyperparathyroidism (HPT) after kidney
transplantation (KTx) is associated with hypercalce-
mia, hypophosphatemia and abnormally high levels of
parathyroid hormone (PTH). In this randomized trial,
cinacalcet was compared to placebo for the treatment
of hypercalcemia in adult patients with persistent HPT
after KTx. Subjects were randomized 1:1 to cinacalcet
or placebo with randomization stratified by baseline
corrected total serum calcium levels (11.2mg/dL
[2.80mmol/L] or >11.2mg/dL [2.80mmol/L]). The
primary end point was achievement of a mean
corrected total serum calcium value <10.2mg/dL
(2.55mmol/L) during the efficacy period. The two key
secondary end points were percent change in bone
mineral density (BMD) at the femoral neck and
absolute change in phosphorus; 78.9% cinacalcet-
versus 3.5% placebo-treated subjects achieved the
primary end point with a difference of 75.4% (95%
confidence interval [CI]: 63.8, 87.1), p< 0.001. There
was no statistical difference in the percent change in
BMD at the femoral neck between cinacalcet and
placebo groups, p¼ 0.266. The difference in the change
in phosphorus between the two arms was 0.45mg/dL
(95% CI: 0.26, 0.64), p< 0.001 (nominal). No new safety
signals were detected. In conclusion, hypercalcemia
and hypophosphatemia were effectively corrected
after treatment with cinacalcet in patients with
persistent HPT after KTx.
Abbreviations: AE, adverse event; ANCOVA, analysis of
covariance; BMD, bonemineral density; CaSR, calcium-
sensing receptor; CKD, chronic kidney disease; EAP,
efficacy assessment phase; eGFR, estimated GFR; FGF-
23, fibroblast growth factor-23; HPT, hyperparathyroid-
ism; iPTH, intact parathyroid hormone; KTx, kidney
transplantation; PTH, parathyroid hormone; RANKL,
receptor activator of nuclear factor kappa-B ligand
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Introduction
Kidney transplantation (KTx) continues to be a desirable
goal of renal replacement therapy. The development of
novel immunosuppressive therapies has led to a tremen-
dous increase in the 1-year survival rates of renal
allografts (1). Accordingly, improving the long-term survival
and quality of life for renal transplant recipients has become
a major focus of posttransplant patient care and includes
prevention of cardiovascular complications (2,3), diabetes
mellitus and fractures secondary to bone disease (4,5).
Secondary hyperparathyroidism (HPT) is a common conse-
quence of end-stage renal disease and often does not
resolve completely after successful KTx. In progressive
renal failure, the ongoing functional demand for parathyroid
hormone (PTH) induces morphological transformations of
parathyroid tissue, including gland hyperplasia and adeno-
ma formation. These morphological transformations are
associated with down-regulation of the vitamin D receptor
and calcium-sensing receptor (CaSR), which result in
parathyroid gland resistance to inhibitory feedback mech-
anisms (6). Successful renal transplantation corrects the
physiologic andmetabolic abnormalities responsible for the
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pathogenesis of secondary HPT (7–9). However, while end-
organ resistance to the action of PTH rapidly wanes parallel
to the recovery of renal function, regression of parathyroid
gland hyperplasia is uncommon. Inappropriately high PTH
levels contribute to common complications such as
hypercalcemia and hypophosphatemia in a substantial
proportion of incident renal transplant recipients (10)—
otherwise referred to as tertiary or persistent HPT.
Hypercalcemia occurs in up to 66% of incident renal
transplant recipients and is most prevalent 3–6months after
transplantation (10,11). Persistent increases in PTH secre-
tion after renal transplantation, can also result in decreased
renal phosphate reabsorption. Consequently, hypophospha-
temia is observed in up to 90% of incident renal transplant
recipients in the early posttransplant period (5,12). Persistent
increases in fibroblast growth factor-23 (FGF-23), a phos-
phaturic hormone, are also thought to contribute to the
development of hypophosphatemia after renal transplanta-
tion (13,14). Although the prevalence of abnormal levels of
PTH, calcium and phosphorus tend to diminish over time,
disorderedmineral metabolismmay persist in some patients
for many years after successful renal transplantation.
Persistent HPT may complicate posttransplant care by
increasing the risk of fractures (5), vascular calcification (3,15)
and renal allograft nephropathy (16,17). These complications
have been associated with significant cardiovascular mor-
bidity and mortality (18).
Given the body of evidence that associates persistent HPT
with complications, clinical management is thought to be
important to optimize clinical outcomes after KTx. Treat-
mentwith loop diuretics and antiresorptive agents to correct
hypercalcemia, or phosphate supplements to correct
hypophosphatemia, may lead to transient improvement,
yet have poor efficacy and may even prove harmful in the
long term. Parathyroidectomy is an option, but limitations
include need for general anesthesia and difficulties associ-
ated with dosing (the amount of parathyroid gland tissue to
be excised) with inherent risks of either unresolved
persistent HPT or frank hypoparathyroidism (19,20).
Studies suggest that calcimimetics might be an effective
alternative to existing therapies. Cinacalcet (Sensipar1/
Mimpara1; Amgen Inc., Thousand Oaks, CA), an allosteric
modulator of the CaSR, has demonstrated efficacy in
decreasing calcium and PTH in patients with secondary
HPT on dialysis (21); and in a number of small, open-label,
single arm, single-center and retrospective studies, cina-
calcet decreased serum calcium and PTH and increased
serum phosphorus levels in renal transplant recipients with
persistent HPT (22–28). In these studies, cinacalcet was
well tolerated with no evidence of adverse effects on
immunosuppressive therapy or allograft function. Because
some single arm studies have suggested that cinacalcet
may have an adverse effect on renal function (29), the
current randomized study is important in evaluating the
safety of cinacalcet in kidney transplant recipients.
To our knowledge, the current study is the first randomized
placebo-controlled trial to evaluate the efficacy and safety
of cinacalcet to lower calcium in renal transplant recipients
with hypercalcemia and persistent HPT. The effects of
cinacalcet on PTH and phosphorus levels were also
assessed. Furthermore, this controlled trial allows for
evaluation of the potential impact of cinacalcet on graft
function and bone mineral density (BMD) during the
treatment of persistent HPT in postkidney transplant
patients.
Materials and Methods
This was a randomized, double-blind, placebo-controlled, multicenter,
global, phase 3 study (Amgen protocol 20062007) to assess the effects
of cinacalcet on hypercalcemia in patients who received a kidney transplant.
Key inclusion criteria include the following at time of screening: a first or
repeat kidney transplant 9 weeks and 24 months before first dose of
study drug; a functional, stable kidney transplant defined as an estimated
GFR (eGFR) 30mL/min/1.73m2 (chronic kidney disease [CKD] stage 3 or
better); corrected total serum calcium >10.5mg/dL (2.63mmol/L), defined
as the mean of two values during screening; and intact PTH (iPTH) >100 pg/
mL (10.6 pmol/L). Subjects were required to have a 4-week washout if they
received cinacalcet for more than 14 days cumulatively posttransplant.
Ongoing use of bisphosphonates, vitamin D analogs, calcium supplements,
phosphate binders or thiazide diuretics were not allowed during the study.
After informed consent (approved by the center’s Internal Review Board),
eligible subjects (18 years of age) were randomized 1:1 to cinacalcet or
placebo. Randomization was stratified by baseline corrected total serum
calcium levels (11.2mg/dL [2.80mmol/L] or >11.2mg/dL [2.80mmol/L]).
At least 30% of subjects were randomized into the high calcium stratum
(>11.2mg/dL [2.80mmol/L]) to capture the spectrum of subjects with mild-
to-moderate (calcium <11.2mg/dL) and moderate-to-severe (calcium
>11.2mg/dL [2.80mmol/L]) disease.
Administration of cinacalcet doses occurred within the range of the current
label with a starting dose of 30mg/day (orally) for either cinacalcet or
placebo. Cinacalcet or placebo (study drugs) were titrated every 4 weeks
during the dose-titration and maintenance phases (maximum dose of
180mg/day) based on iPTH level, corrected total serum calcium value and
safety evaluations. Investigators were instructed to decrease the dose of
study drug if there were two consecutive corrected total serum calcium
values<8.4mg/dL (2.1mmol/L) or three consecutive values of iPTH<35 pg/
mL (3.7 pmol/L) or if the subject experienced an adverse event (AE) that
required a decrease in dose. With the exception of medications previously
noted, concomitant medications were permitted to resolve any signs or
symptoms of AEs and manage persistent HPT at the discretion of the
investigator in accordance with local practice guidelines.
Samples were collected at protocol specified intervals during the dose-
titration phase (day 1, weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20), efficacy
assessment phase (EAP; weeks 22, 24 and 26), maintenance phase (weeks
34, 42 and 52) and posttreatment follow-up phase (week 56). Blood
samples were taken for measurement of: creatinine, iPTH, FGF-23
(Immunotopics, Inc., San Clemente, CA), total serum calcium and albumin
(for corrected calcium), serum phosphorus and 25(OH)D3. Measures of
BMD at the femoral neck by dual X-ray absorptiometry (Synarc Imaging,
Newark, CA) were collected at baseline and week 52. Synarc provided
oversight for reading the imaging scans and standardizing machines across
all sites.
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Statistical analysis
A sample size of 100 subjects (50 per arm) was estimated to provide 91%
power to achieve a statistical significance of 0.05 (two-sided) using the chi-
square test. This assumed a response rate for the correction in total serum
calcium of 35% in the placebo group and 70% in the cinacalcet group, and
13%subjects being excluded in the analyses due to loss of kidney transplant
function.
Statistical considerations were based on the hypothesis that 6 months of
treatment with cinacalcet would enable a greater proportion of subjects to
achieve a mean corrected total serum calcium concentration <10.2mg/dL
(2.55mmol/L) during the EAP, compared with those who received placebo.
The primary end point is the achievement of a mean corrected total serum
calcium value <10.2mg/dL (2.55mmol/L) during the EAP. Hierarchical
testing procedure (30) was used to test the primary and the two secondary
end points. First, the primary end point was tested at a significance level of
0.05. If the primary end point achieved a significant result, the two key
secondary end points were tested using the same hierarchical testing
procedure. Among the two key secondary end points, the percent change in
BMD was tested first; if the result achieved statistical significance, the
change in serum phosphorus would be tested. Comparisons of the
proportion of subjects, between the two treatment groups, achieving the
primary end point was performed using a Cochran–Mantel–Haenszel test
stratified by baseline corrected total serum calcium level (11.2mg/dL
[2.80mmol/L] and >11.2mg/dL [2.80mmol/L]). Percent change or change
from baseline in BMD parameters, mean total serum calcium, iPTH,
phosphorus and kidney transplant function (eGFR) during the EAP or
week 52 was compared between the two treatment groups using an
analysis of covariance (ANCOVA). Baseline corrected total serum calcium
was used as a covariate. The eGFR was calculated by the MDRD formula.
The frequency of safety end points was tabulated by treatment group.
Results
Subject disposition and baseline demographics
A total of 114 subjects were randomized to receive
cinacalcet (N¼ 57) or placebo (N¼57), while 104 (91.2%)
subjects completed the study and 10 (8.8%) discontinued
study, of which five were in the cinacalcet group.
Of the total number of subjects enrolled, mean (SD) age
was 52.3 (10.3) yearswith 55.3% subjectsmale and 81.6%
white or Caucasian. Mean (SD) dialysis vintage was 62.4
(40.1) months and age of most recent kidney transplant
was 7.2 (4.5) months. These characteristics were similar
between groups. Details of subject demographics are
summarized in Table 1. Table 2 summarizes the number of
subjectswithin each dose category at the end of each study
phase for the cinacalcet-treated subjects. For cinacalcet
and placebo, the mean (SD) average daily dose for
investigational product was 61.6 (31.2)mg and 129.5
(29.1)mg, respectively.
Mean (SD) baseline iPTH was 327.7 (262.6) pg/mL for the
cinacalcet group versus 307.5 (180.5) pg/mL for the placebo
group. Mean (SD) baseline corrected total serum calcium
was 11.28 (0.41)mg/dL for the cinacalcet group versus
11.31 (0.50)mg/dL for the placebo group. Mean (SD)
baseline serum phosphorus was 2.66 (0.54)mg/dL for the
cinacalcet group versus 2.48 (0.52)mg/dL for the placebo
group. Baselinemean (SD) eGFR valueswere 57.00 (17.31)
and 54.68 (14.79)mL/min/1.73m2 for the cinacalcet and
placebo groups, respectively. Laboratory values are pre-
sented in Table 3.
Primary end point
Overall, the proportion of subjects achieving the primary
end point (i.e. the achievement of a mean corrected total
serum calcium value <10.2mg/dL [2.55mmol/L]) was
78.9% and 3.5% for the cinacalcet and placebo groups,
respectively. The difference (cinacalcet  placebo) in
proportions was 75.4% (95% confidence interval [CI]:
63.8, 87.1), whichwas statistically significant (p< 0.001).
The odds ratio (cinacalcet/placebo) was 91.41 (95% CI:
18.76, 445.41). In the corrected total serum calcium
11.2mg/dL stratum there were 20/23 (87.0%) and 2/22
(9.1%) subjects who achieved the primary end point in
the cinacalcet and placebo arms, respectively; whereas
in the corrected total serum calcium >11.2mg/dL
stratum there were 25/34 (73.5%) and 0/35 (0%)
who achieved the primary end point in the respective
groups.
Table 1: Subject demographics and characteristics
Cinacalcet /(N¼57) Placebo (N¼57) Total (N¼114)
Age, mean (SD) 53.0 (10.7) 51.7 (9.9) 52.3 (10.3)
Sex, n (%)
Male 31 (54.4) 32 (56.1) 63 (55.3)
Female 26 (45.6) 25 (43.9) 51 (44.7)
Race, n (%)
White 47 (82.5) 46 (80.7) 93 (81.6)
Black 5 (8.8) 4 (7.0) 9 (7.9)
Other 5 (8.7) 7 (12.3) 12 (10.5)
Blood pressure, mean (SD)
Systolic (mmHg) 133.9 (18.4) 129.9 (14.0) 131.9 (16.4)
Diastolic (mmHg) 77.4 (10.4) 77.7 (9.3) 77.5 (9.8)
Dialysis vintage, mean (SD), months 62.0 (44.2) 62.7 (35.8) 62.4 (40.1)
Age of most recent kidney transplant, mean (SD), months 7.8 (5.6) 6.5 (3.0) 7.2 (4.5)
Number of subjects exposed to cinacalcet, n (%) 36 (63.2) 35 (61.4) 71 (62.3)
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BMD and bone turnover markers
Mean (SE) percent changes in BMD are presented in
Table 4 and mean (SE) Z scores are presented in Table S1.
Mean (SE) percent change in BMD at the femoral neck (first
secondary end point) measured from baseline to week 52
by treatment group was 2.16% (1.07%) in the cinacalcet
group compared to 0.73% (0.63%) in the placebo group.
Least square mean estimate for the difference in the
percent change in BMDbetween the two treatment groups
(cinacalcet  placebo) is 1.41% with a 95% CI of (1.10,
3.93). Test of treatment effect adjusting for baseline
corrected total calcium level yields a p-value of 0.266.
Markers of bone turnover are presented in Table 5. For
blood alkaline phosphatase, osteocalcin and urine N-
telopeptide, the mean values decreased over time from
baseline to week 52 with some fluctuation in between in
the cinacalcet arm while the mean values decreased over
time from baseline to week 52 in the placebo arm. For 25
(OH)D3, the mean increased over time from baseline to
week 52 for both cinacalcet and placebo arm.
Serum calcium and phosphorus
Corrected total serum calcium decreased from baseline to
EAP such that the mean (SE) change was1.53 (0.10)mg/
dL for the cinacalcet group and 0.14 (0.07)mg/dL for
the placebo group (Figure 1). Results from the ANCOVA
analysis yielded a nominal p-value of <0.001 for a
difference of 1.39mg/dL (95% CI: 1.62, 1.16)
between the two groups. The mean (SE) change in serum
phosphorus from baseline to EAP was 0.52 (0.07)mg/dL
for the cinacalcet group and 0.07 (0.06)mg/dL for the
placebo group (Figure 2). The least square mean estimate
for the difference in the absolute change in mean serum
phosphorus from baseline to EAP between the two
treatment groups (cinacalcet  placebo) was 0.45mg/dL
(95% CI: 0.26, 0.64), p< 0.001. Because the first second-
ary end point (BMD) was not statistically significant, the
second secondary end point of phosphorus was not
statistically tested. Subsequently, the p-value was consid-
ered nominal.
Table 2: Summary of cinacalcet dose level (mg/day) by study
phase
Dose
level
(mg/day)
Cinacalcet (N¼57)
End of
titration
(N1¼57)
End of
EAP
(N1¼52)
End of
maintenance
(N1¼53)
End of
study
(N1¼57)
n (%) n (%) n (%) n (%)
30 17 (29.8) 15 (28.8) 17 (32.1) 19 (33.3)
60 21 (36.8) 19 (36.5) 17 (32.1) 18 (31.6)
90 11 (19.3) 10 (19.2) 11 (20.8) 12 (21.1)
120 5 (8.8) 3 (5.8) 3 (5.7) 3 (5.3)
180 3 (5.3) 5 (9.6) 5 (9.4) 5 (8.8)
EAP, efficacy assessment phase; %, n/N1.
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Plasma PTH and FGF-23
iPTH decreased from baseline to EAP such that the mean
(SE) change was 127.9 (33.7) pg/mL in the cinacalcet
group and 10.6 (14.1) pg/mL in the placebo group
(Figure 3). The ANCOVA analysis yielded a nominal p-
value of 0.002 for a difference of 117.2 pg/mL (95% CI:
189.9, 44.6) between the two groups. Mean (SE)
change of FGF-23 from baseline to week 26 was 3.54
(2.19) pg/mL and 0.20 (2.48) pg/mL for the cinacalcet and
placebo groups, respectively based on subjects with both
baseline and week 26 measurements. Mean (SE) change
from baseline to week 52 was 7.06 (2.06) pg/mL and
1.18 (4.25) pg/mL for the cinacalcet and placebo groups,
respectively.
eGFR and urinary calcium
Data for eGFR indicated that renal function remained stable
over timewith no difference between the groups (Figure 4).
The ANCOVA analysis on change from baseline to week 52
yielded a nominal p-value of 0.842 for a difference of
0.40mL/min/1.73m2 (95%CI:4.37, 3.57) from baseline
to week 52 between the two groups. Urinary calcium (UCa)
to urinary creatinine (UCr) ratio was calculated. The mean
(SE) UCa/UCr ratio is 0.17 (0.02)mg/mg for cinacalcet arm
and 0.13 (0.01)mg/mg for placebo arm at baseline. The
mean (SE) change from baseline was 0.03 (0.02)mg/mg
for the cinacalcet arm and 0.01 (0.02)mg/mg for the
placebo arm at week 52.
Safety
Two (3.5%) subjects in the cinacalcet group and three
(5.3%) subjects in the placebo group discontinued the
study drug due to an AE. The most frequently reported
treatment-emergent AE in the cinacalcet group was
diarrhea: cinacalcet (n¼ 9, 15.8%) versus placebo (n¼3,
5.3%) groups. One subject randomized to the cinacalcet
group had a fatal AE and died ofmetastatic adenocarcinoma
of the lung. Due to the subject’s history, the investigator
reported that therewas no reasonable association between
the event and the study drug. Furthermore, one subject
from the cinacalcet group experienced a foot fracture, while
two subjects from the placebo group developed a femoral
neck and a vertebral fracture. No new safety risks were
identified.
Discussion
This randomized, double-blind, placebo-controlled study
demonstrated that cinacalcet is a highly effective treatment
option for correcting serum calcium and phosphorous
levels in renal transplant recipients with persistent HPT.
Almost 80% of patients with hypercalcemia and persistent
HPT treated with cinacalcet versus 4% treated with
placebo achieved a corrected total serum calcium value
<10.2mg/dL. Achievement of target calcium levels was
accompanied by an increase in phosphorus and a decrease
in PTH levels without requiring maximal escalation of
cinacalcet dose over time. There was no statistically
significant difference between treatment groups for the
secondary end point of percent change in BMD, nor were
there remarkable differences in bone turnovermarkers. It is
worth noting that renal transplant functionwas not affected
Table 4: Mean (SE) bone mineral density (BMD) at baseline and
week 52 with percent change in BMD at the femoral neck, lumbar
spine and distal 1/3 radius
BMD at femoral neck (g/cm2)
n Cinacalcet n Placebo
Baseline 56 0.737 (0.023) 57 0.732 (0.022)
Week 52 52 0.751 (0.024) 49 0.728 (0.024)
% Change 52 2.16 (1.07) 49 0.73 (0.63)
BMD at lumbar spine (g/cm2)
n Cinacalcet n Placebo
Baseline 56 0.985 (0.021) 55 0.966 (0.29)
Week 52 52 0.991 (0.021) 48 0.963 (0.031)
% Change 52 0.598 (0.827) 48 1.172 (0.766)
BMD at distal 1/3 radius (g/cm2)
n Cinacalcet n Placebo
Baseline 53 0.653 (0.010) 56 0.622 (0.016)
Week 52 48 0.641 (0.012) 46 0.602 (0.018)
% Change 47 2.714 (0.781) 46 1.992 (0.591)
Table 5: Markers of bone turnover, mean (SD)
Cinacalcet (N¼ 57) Placebo (N¼ 57)
Baseline Week 12 Week 26 Week 52 Baseline Week 12 Week 26 Week 52
BALP (ng/mL) 30.93 (14.99) 35.58 (21.52) 33.82 (22.43) 26.30 (13.68) 34.73 (25.46) 33.08 (28.49) 27.14 (16.97) 23.85 (13.47)
Urine NTx (nmol/L) 104.77 (60.69) 125.08 (83.43) 118.93 (90.48) 82.42 (50.21) 116.78 (92.85) 94.42 (70.35) 93.31 (72.91) 80.57 (54.86)
Osteocalcin (ng/mL) 74.37 (39.27) 77.37 (41.89) 76.72 (42.21) 69.43 (37.22) 79.39 (59.37) 76.89 (56.08) 68.17 (43.13) 62.85 (36.31)
25(OH)D3 (ng/mL) 18.49 (8.92) 21.33 (9.22) 23.34 (8.97) 22.96 (9.59) 20.48 (10.54) 20.83 (9.50) 21.60 (9.87) 22.67 (8.95)
BALP, bone-specific alkaline phosphatase (ng/mL); urine NTx, urine N-telopeptide.
Normal ranges for each analyte: BALP male 8.8–30 ng/mL, female 5.7–22 ng/mL; urine NTx male 11–103 nmol/mmol, female 10–110 nmol/mmol; osteocalcin
7.3–38.5 ng/mL; 25(OH)D3 9.2–37.6 ng/mL.
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Figure 1: Mean (SE) corrected total serum calcium (mg/dL) over time. PTFU, posttreatment follow-up.
Figure 2: Mean (SE) phosphorus (mg/dL) over time. PTFU, posttreatment follow-up.
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by treatment with cinacalcet. Furthermore, no apparent
interaction with standard immunosuppressive therapies
and cinacalcet was observed (data not shown). In addition,
no new AEs were identified. As such, this study confirms
and extends data from previous small and/or uncontrolled
intervention studies regarding the efficacy and safety of
cinacalcet when used to treat hypercalcemia and persistent
HPT in renal transplant recipients (22,25,27,28,31–33).
Figure 3: Mean (SE) intact PTH (iPTH) (pg/mL) at scheduled visits (baseline, weeks 26 and 52). PTFU, posttreatment follow-up.
Figure 4: Mean (SE) estimated GFR (eGFR) (mL/min/1.73m2) over time. PTFU, posttreatment follow-up.
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HPT does not completely resolve in a substantial proportion
of kidney transplant recipients (34). Risk factors for
persistent HPT after renal transplantation include increased
dialysis vintage and more severe secondary HPT prior to
transplantation (10,35). Despite successful KTx, persistent
HPT has been observed in 17% of patients to as high
as 50% up to 2 years after transplantation. In addition,
hypercalcemia is seen in up to 66% of patients within
3 months of surgery and decreases to 10–40% 2 years
posttransplantation; whereas, hypophosphatemia occurs
in up to 68% of patients 3 months posttransplantation
and decreases to 16% after 2 years (10). Quantifying the
proportion of patients with underlying persistent HPT has
been difficult due to the absence of clearly defined
guidelines for the disease. Adding to this difficulty is the
inability to discern the relative contributions from parathy-
roid hyperplasia in persistent HPT in optimally functioning
allografts versus recurrent secondary HPT in marginally
functioning allografts. The trends in calcium, phosphorus
and PTH in placebo-treated subjects confirm that sponta-
neous correction of hypercalcemic HPT is uncommon
at least within the first 2 years of renal transplantation.
The increases in calcium and PTH and the decrease in
phosphorus levels after withdrawal of cinacalcet to
comparable values in the placebo arm support the chronic
nature of posttransplant HPT (36) wherein cinacalcet may
not alter the natural history. Subsequently, long-term
medical treatment may be required. To date, parathyroid-
ectomy is the only available, approved therapeutic option.
When surgical treatment is indicated for those with severe
HPT, refractory hypercalcemia or evident clinical sequel-
ae (37), parathyroidectomy has not clearly demonstrated
tangible health outcomes (38) though it has proven
efficacy (39). Thus, under similar indications and unclear
outcomes, a medical treatment may provide an alternative
to surgery. It should, however, be emphasized that at
present cinacalcet is not approved for use in postrenal
transplant patients.
Although the main alteration in bone remodeling is a
decrease in bone formation against persistent bone
resorption (36), there remains the hypothesis that treating
persistent HPT with hypercalcemia may curb morbidity
risks such as fractures, which occurs in approximately 10–
25%of all renal transplant recipients over their lifetime (40–
45). In fact, fracture risk is substantially higher in renal
transplant recipients than in recipients of other solid organs.
Recent clinical evidence suggests that risk factors specific
to the renal transplant setting, such as persistent HPT, may
be involved (4,5,46–49). As PTH is a master regulator of
bone remodeling, it activates osteoblasts both directly and
indirectly via decreased expression of the osteocyte-
derived Wnt antagonist sclerostin. The activation of
osteoclasts by PTH involves the RANKL (receptor activator
of nuclear factor kappa-B ligand) signaling pathway. In
addition, hypophosphatemia may blunt PTH-mediated
osteoblastogenesis and, thus, contribute to the uncoupling
of bone resorption and formation (36). Thus, modulating
PTHmay affect the underlying cellular bone physiology that
contributes to fracture in a particularly vulnerable popula-
tion. Furthermore, correction of hypercalcemia may allow
for the use of vitamin D supplementation. This may prove
beneficial as renal transplant recipients are often nutritional
vitamin D deficient (31).
Of note, FGF-23 levels were not elevated in this study, and
no significant changes were observed during the 1-year
period or between treatment groups. These data, support
recent experimental evidence pointing to interactions
between calcium and phosphorus in the regulation of
FGF-23 production (50,51). Because increases of FGF-23 in
renal transplant patients have been correlated with both
poor graft function and patient survival (52), it is reassuring
that levels remained low.
The present study confirms that cinacalcet is well tolerated
in postrenal transplant recipients. In addition, it supports
studies that have shown that cinacalcet has no clinically
relevant interaction with standard immunosuppressive
drugs (53). The most frequently reported treatment-
emergent AE in the cinacalcet group was diarrhea, similar
towhat has been reported in other CKD cohorts (7,9,21,54).
Previously, concerns have been raised about decreases in
renal function following cinacalcet therapy for the treat-
ment of persistent HPT including limited, but significant
drops in eGFR (29). However, renal function in these
studies returned to baseline after cessation of cinacalcet,
suggesting a hemodynamic rather than a structural
mechanism. A similar acute decline of renal function has
been observed following parathyroidectomy (19); however,
long-term graft outcome was not affected by this proce-
dure (55). It is encouraging that in the current trial,
cinacalcet treatment had no negative impact on renal
function and eGFR levels remained relatively unchanged in
both treatment arms. Although this trial confirms the
efficacy and safety of cinacalcet with regard to improve-
ment in both hypercalcemia and elevated PTH randomized
trials designed to evaluate the impact of treatment on
clinical outcomes in this patient population have not been
conducted. The choice to treat hypercalcemia, including
cost considerations, risk of prolonged drug exposure and
perceived benefit, remains a decision by the physician and
patient.
Limitations of study
The present study did not aim to investigate the impact of
cinacalcet on the incidence of fractures in renal transplant
recipients, yet the effect of cinacalcet on BMDwas studied
as a secondary end point. The hip was selected as the
evaluation site as it includes cortical bone andmay have the
greatest impact on morbidity or mortality when it under-
goes fracture. Albeit no intergroup differences in change of
BMD could be demonstrated, this may be due to
insufficient power to determine a statistical difference as
well as the short observation period. Data on bone
histomorphometry are unfortunately lacking in the present
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study. Studies evaluating bone histomorphometry in renal
transplant recipients are limited and yielded heterogeneous
or even contradictory data. This heterogeneity is likely due
to indication bias and variable time interval since transplan-
tation (36). It should be acknowledged that in a recent bone
biopsy study in 10 renal transplant recipients with
hypercalcemic HPT a high proportion of low bone disease
was observed (56). Additional bone biopsy studies are
required to evaluate the impact of cinacalcet on bone
histomorphometry. This was a placebo-controlled, blinded
study; however, PTH and calcium levelswere not blinded to
investigators as dosing decisions required assessment of
both. Thismay have compromised the blinding of treatment
assignment.
Conclusion
These findings demonstrate the effectiveness and safety of
cinacalcet to correct hypercalcemia in renal transplant
recipients. An increase in phosphorus and decrease in PTH
was observed in the cinacalcet-treated group, consistent
with the known mechanism of action of cinacalcet and its
effect on parathyroid function. Cinacalcet can be consid-
ered a therapeutic option for the treatment of hypercalce-
mia and persistent HPT. Providing a medical alternative to
parathyroidectomy for renal transplant patients allows for
the individualization of therapy and choice for patients and
physicians. These data support further investigation of
cinacalcet in the renal transplant population, focusing not
only on biochemical and hormonal parameters, but also on
clinical outcomes.
Acknowledgments
The authors wish to thank Holly Tomlin (employee and stockholder, Amgen
Inc., Thousand Oaks, CA) for her medical writing and journal formatting
assistance, and Lulu Sterling and Marie-Louise Trotman for their statistical
analysis support. All authors contributed to the development of the
manuscript per ICMJE criteria and approved the final version submitted to
the journal. This study was funded by Amgen Inc.
Disclosure
The authors of this manuscript have conflicts of interest to
disclose as described by the American Journal of Trans-
plantation. This study was funded by Amgen Inc. K Cooper,
H Deng and S Yue are employees and stockholders of
Amgen Inc. P Evenepoel has been a member of advisory
boards, received grant support and speaker’s fees from
Amgen. H Holdaas has received lecture fees from Amgen,
AstraZeneca, Astellas, Bristol-Myers Squibb and Novartis.
P Messa received research funds from Fresenius and
speaker board fees from Fresenius, Abbvie and Amgen. JV
Torregrosa has given talks at sponsored meetings by
Abbvie, Amgen, Fresenius, Sanofi and Shire. RP Wuthrich
has been a clinical investigator, a recipient of grant support
and a member of advisory boards for Amgen.
References
1. Sayegh MH, Carpenter CB. Transplantation 50 years later—
Progress, challenges, and promises. N Engl J Med 2004; 351:
2761–2766.
2. Marechal C, Coche E, Goffin E, et al. Progression of coronary artery
calcification and thoracic aorta calcification in kidney transplant
recipients. Am J Kidney Dis 2012; 59: 258–269.
3. Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary
artery calcification in renal transplantation and the role of
secondary hyperparathyroidism and inflammation. Clin J Am Soc
Nephrol 2009; 4: 685–690.
4. Giannini S, Sella S, Silva Netto F, et al. Persistent secondary
hyperparathyroidism and vertebral fractures in kidney transplanta-
tion: Role of calcium-sensing receptor polymorphisms and vitamin
D deficiency. J Bone Miner Res 2010; 25: 841–848.
5. Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroid-
ism is a major risk factor for fractures in the 5 years after kidney
transplantation. Am J Transplant 2013; 13: 2653–2663.
6. Drueke TB. Therapeutic failure of cinacalcet in a renal transplant
patient. Nephrol Dial Transplant 2006; 21: 824; author reply 824–
825.
7. Block GA, Zeig S, Sugihara J, et al. Combined therapy with
cinacalcet and low doses of vitamin D sterols in patients with
moderate to severe secondary hyperparathyroidism. Nephrol Dial
Transplant 2008; 23: 2311–2318.
8. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathy-
roidism: Pathogenesis, disease progression, and therapeutic
options. Clin J Am Soc Nephrol 2011; 6: 913–921.
9. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI
bonemetabolism and disease treatment goalswith cinacalcet HCl.
Kidney Int 2005; 67: 760–771.
10. Evenepoel P, Claes K, Kuypers D, et al. Natural history of
parathyroid function and calcium metabolism after kidney trans-
plantation: A single-centre study. Nephrol Dial Transplant 2004; 19:
1281–1287.
11. Stavroulopoulos A, Cassidy MJ, Porter CJ, et al. Vitamin D status
in renal transplant recipients. Am J Transplant 2007; 7: 2546–
2552.
12. Torregrosa JV, Bergua C,Martinez deOsabaMJ, et al. Evolution of
secondary hyperparathyroidism after kidney transplantation in
patients receiving cinacalcet on dialysis. Transplant Proc 2009; 41:
2396–2398.
13. Serra AL, Wuhrmann C, Wuthrich RP. Phosphatemic effect of
cinacalcet in kidney transplant recipients with persistent hyper-
parathyroidism. Am J Kidney Dis 2008; 52: 1151–1157.
14. Trombetti A, Richert L, Hadaya K, et al. Early post-transplantation
hypophosphatemia is associated with elevated FGF-23 levels. Eur
J Endocrinol 2011; 164: 839–847.
15. Meneghini M, Regalia A, Alfieri C, et al. Calcium and osteopro-
tegerin levels predict the progression of the abdominal aortic
calcifications after kidney transplantation. Transplantation 2013;
96: 42–48.
16. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of
chronic allograft nephropathy. N Engl J Med 2003; 349: 2326–
2333.
17. Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic
allograft nephropathy after renal transplantation: A protocol biopsy
study. Kidney Int 2005; 67: 341–348.
Cinacalcet to Correct Hypercalcemia in Persistent HPT
2553American Journal of Transplantation 2014; 14: 2545–2555
18. Sarnak MJ, Levey AS. Cardiovascular disease and chronic
renal disease: A new paradigm. Am J Kidney Dis 2000; 35:
S117–S131.
19. Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidecto-
my on renal graft function, blood pressure and serum lipids in
kidney transplant recipients: A single centre study. Nephrol Dial
Transplant 2005; 20: 1714–1720.
20. Evenepoel P, Kuypers D, Maes B, et al. Persistent hyperparathy-
roidism after kidney transplantation requiring parathyroidectomy.
Acta Otorhinolaryngol Belg 2001; 55: 177–186.
21. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for
secondary hyperparathyroidism in patients receiving hemodialysis.
N Engl J Med 2004; 350: 1516–1525.
22. El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience
with cinacalcet use in persistent secondary hyperparathyroidism
after kidney transplantation. Transplantation 2007; 83: 546–
549.
23. Leca N, Laftavi M, Gundroo A, et al. Early and severe
hyperparathyroidism associated with hypercalcemia after renal
transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391–
2395.
24. Apostolou T, Damianou L, Kotsiev V, et al. Treatment of severe
hypercalcemia due to refractory hyperparathyroidism in renal
transplant patients with the calcimimetic agent cinacalcet. Clin
Nephrol 2006; 65: 374–377.
25. Bergua C, Torregrosa JV, Cofan F, et al. Cinacalcet for the
treatment of hypercalcemia in renal transplanted patients with
secondary hyperparathyroidism. Transplant Proc 2007; 39: 2254–
2255.
26. Kruse AE, Eisenberger U, Frey FJ, et al. The calcimimetic
cinacalcet normalizes serum calcium in renal transplant patients
with persistent hyperparathyroidism. Nephrol Dial Transplant
2005; 20: 1311–1314.
27. Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of
hypercalcemia with cinacalcet in renal transplant recipients with
persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20:
1315–1319.
28. Szwarc I, Argiles A, Garrigue V, et al. Cinacalcet chloride is
efficient and safe in renal transplant recipients with posttra-
nsplant hyperparathyroidism. Transplantation 2006; 82: 675–
680.
29. Henschkowski J, Bischoff-Ferrari HA, Wuthrich RP, et al. Renal
function in patients treated with cinacalcet for persistent
hyperparathyroidism after kidney transplantation. Kidney Blood
Press Res 2011; 34: 97–103.
30. Westfall PH, Tobias RD, Rom D, et al. Multiple comparisons,
multiple tests using SAS. Cary, NC: SAS Institute Inc., 1999.
31. Borstnar S, Erzen B, Gmeiner Stopar T, et al. Treatment of
hyperparathyroidism with cinacalcet in kidney transplant recipi-
ents. Transplant Proc 2010; 42: 4078–4082.
32. Paschoalin RP, Torregrosa JV, Barros X, et al. Cinacalcet de novo in
persistent hypercalcemia after kidney transplantation secondary to
hyperparathyroidism: Long-term follow-up and effect of withdraw-
al. Transplant Proc 2012; 44: 2376–2378.
33. Pinho LR, Ribeiro Santos MJ, Pestana Vasconcelos M. Cinacalcet
in the treatment of persistent hyperparathyroidism after kidney
transplantation. Clin Nephrol 2011; 75: 263–268.
34. Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and
mineral metabolism in kidney transplant patients—A review. Am J
Nephrol 2008; 28: 246–253.
35. Messa P, Sindici C, Cannella G, et al. Persistent secondary
hyperparathyroidism after renal transplantation. Kidney Int 1998;
54: 1704–1713.
36. Evenepoel P. Recovery versus persistence of disordered mineral
metabolism in kidney transplant recipients. Semin Nephrol 2013;
33: 191–203.
37. Eigelberger MS, Cheah WK, Ituarte PH, et al. The NIH criteria for
parathyroidectomy in asymptomatic primary hyperparathyroidism:
Are they too limited? Ann Surg 2004; 239: 528–535.
38. Abdelhadi M, Nordenstrom J. Bone mineral recovery after
parathyroidectomy in patients with primary and renal hyperpara-
thyroidism. J Clin Endocrinol Metab 1998; 83: 3845–3851.
39. Sadideen HM, Taylor JD, Goldsmith DJ. Total parathyroidectomy
without autotransplantation after renal transplantation for tertiary
hyperparathyroidism: Long-term follow-up. Int Urol Nephrol 2012;
44: 275–281.
40. Abbott KC, Oglesby RJ, Hypolite IO, et al. Hospitalizations for
fractures after renal transplantation in the United States. Ann
Epidemiol 2001; 11: 450–457.
41. Nikkel LE, Hollenbeak CS, Fox EJ, et al. Risk of fractures after renal
transplantation in the United States. Transplantation 2009; 87:
1846–1851.
42. Nisbeth U, Lindh E, Ljunghall S, et al. Increased fracture rate in
diabetes mellitus and females after renal transplantation. Trans-
plantation 1999; 67: 1218–1222.
43. O’Shaughnessy EA, Dahl DC, Smith CL, et al. Risk factors for
fractures in kidney transplantation. Transplantation 2002; 74: 362–
366.
44. Palmer SC, Strippoli GF, McGregor DO. Interventions for
preventing bone disease in kidney transplant recipients: A
systematic review of randomized controlled trials. Am J Kidney
Dis 2005; 45: 638–649.
45. Vautour LM,Melton LJ 3rd, Clarke BL, et al. Long-term fracture risk
following renal transplantation: A population-based study. Osteo-
poros Int 2004; 15: 160–167.
46. Cruz DN, Brickel HM, Wysolmerski JJ, et al. Treatment of
osteoporosis and osteopenia in long-term renal transplant patients
with alendronate. Am J Transplant 2002; 2: 62–67.
47. Heaf J, Tvedegaard E, Kanstrup IL, et al. Bone loss after renal
transplantation: Role of hyperparathyroidism, acidosis, cyclospor-
ine and systemic disease. Clin Transplant 2000; 14: 457–
463.
48. Setterberg L, Sandberg J, Elinder CG, et al. Bone demineralization
after renal transplantation: Contribution of secondary hyperpara-
thyroidismmanifested by hypercalcaemia. Nephrol Dial Transplant
1996; 11: 1825–1828.
49. Ghanekar H, Welch BJ, Moe OW, et al. Post-renal transplantation
hypophosphatemia: A review and novel insights. Curr Opin
Nephrol Hypertens 2006; 15: 97–104.
50. Quinn SJ, Thomsen AR, Pang JL, et al. Interactions between
calcium and phosphorus in the regulation of the production of
fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab
2013; 304: E310–E320.
51. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, et al. Calcium
deficiency reduces circulating levels of FGF23. J Am Soc Nephrol
2012; 23: 1190–1197.
52. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth
factor 23 is a risk factor for kidney transplant loss and mortality. J
Am Soc Nephrol 2011; 22: 956–966.
53. Falck P, Vethe NT, Asberg A, et al. Cinacalcet’s effect on the
pharmacokinetics of tacrolimus, cyclosporine and mycophenolate
in renal transplant recipients. Nephrol Dial Transplant 2008; 23:
1048–1053.
54. EVOLVE Trial Investigators, ChertowGM, Block GA, et al. Effect of
cinacalcet on cardiovascular disease in patients undergoing
dialysis. N Engl J Med 2012; 367: 2482–2494.
Evenepoel et al
2554 American Journal of Transplantation 2014; 14: 2545–2555
55. Evenepoel P, Claes K, Kuypers DR, et al. Parathyroidectomy after
successful kidney transplantation: A single centre study. Nephrol
Dial Transplant 2007; 22: 1730–1737.
56. Borchhardt KA, Diarra D, Sulzbacher I, et al. Cinacalcet
decreases bone formation rate in hypercalcemic hyperparathy-
roidism after kidney transplantation. Am J Nephrol 2010; 31:
482–489.
Supporting Information
Additional Supporting Information may be found in the
online version of this article.
Table S1: Mean (SE) BMD Z scores.
Cinacalcet to Correct Hypercalcemia in Persistent HPT
2555American Journal of Transplantation 2014; 14: 2545–2555
